Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia

  • US 5,738,873 A
  • Filed: 09/27/1996
  • Issued: 04/14/1998
  • Est. Priority Date: 09/27/1996
  • Status: Expired due to Fees
First Claim
Patent Images

1. A pharmaceutical formulation for the treatment of a disorder having muscular hypotonia as a symptom, selected from the group of an Alzheimer'"'"'s disease, atrophy of the brain, atrophy of the cerebellum, Fragile X syndrome, mental retardation of unknown causes, multiple anomalies in the chromosomes, deletion in one or more chromosome, and fragility in a chromosome other than the X chromosome, said formulation comprising non toxic quantities of the following components in a pharmaceutically acceptable excipient:

  • a. about 0.05 to about 200 mg of gamma amino burytic acid (GABA);

    b. about 50 to about 300 mg of an antioxidant selected from the group consisting of vitamin E, ascorbic acid, and mixtures thereof;

    c. about 100 to about 300 mg of folic acid;

    d. about 0.05 to about 0-5 mg of a nicotinamide selected from the group consisting of nicotinamide and pharmaceutically acceptable salts thereof; and

    e. about 25 to about 100 mg of a lithium salt selected from the group consisting of lithium carbonate, lithium bromide, lithium chloride, and lithium acetate.

View all claims

    Thank you for your feedback